ReviewJournal for immunotherapy of cancer2025
Cancer immunotherapy clinical trials to support urgently needed access in low- and middle-income countries: a report from the SITC global access and impact committee.
Review in Journal for immunotherapy of cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Clinical outcomes of the chemo-free approach in relapsed/refractory follicular lymphoma: A network meta-analysis.British journal of haematology · 2026Pooled it
- Integrated Immune Escape in Cervical Cancer: HLA-I Dysfunction and Immune Checkpoint Signaling.International journal of molecular sciences · 2026Review
- Review
- Review
- Endobronchial Intratumoral Immuno- and Gene Therapies in Lung Cancer: Mechanisms of Local Delivery, Systemic Immune Effects, and Global Feasibility.International journal of molecular sciences · 2026Review
- Emerging trends in the global burden of colorectal cancer.Nature reviews. Clinical oncology · 2026Review
- Immunological Determinants of Oncogenic Virus-Driven Cancers in Africa: Mechanisms, Co-Infections and Public Health Challenges.Pathogens (Basel, Switzerland) · 2026Review
- GLP-1 receptor agonists at immune checkpoint inhibitor initiation with immune-related and supportive-care outcomes in patients with cancer and overweight or obesity without diabetes: a target trial emulation.Cancer immunology, immunotherapy : CII · 2026Article
- Applying biotechnology to overcome cancer drug resistance and improve public health outcomes.Osong public health and research perspectives · 2026Article
- Alohomora! A Letter to the Keeper of the Key.Global journal on quality and safety in healthcare · 2026Article
- Real-world evaluation of bevacizumab plus platinum and paclitaxel for advanced cervical cancer: a single-arm study from Syria.Ecancermedicalscience · 2026Article
- Biomarker-driven neoadjuvant immunotherapy in triple-negative breast cancer: emerging therapeutic targets FOXP3 and WT1.Frontiers in immunology · 2026Review
- Real-world efficacy and safety profile of low-dose cadonilimab in recurrent or metastatic cervical cancer as first-line therapy.Frontiers in immunology · 2026Article
- Real-World Outcomes of Immune Checkpoint Inhibitors in Melanoma, Including Acral and Mucosal Subtypes: A Retrospective Cohort Study From a Latin American Center.Journal of skin cancer · 2026Article
- Immunotherapy Landscape for Acute Lymphoblastic Leukaemia (ALL) in Malaysia: A Qualitative Study Among Healthcare Professionals From Two National Referral Centres.Cancer control : journal of the Moffitt Cancer CenterArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
26 authors.
Funding
Abstract
Cancer is rapidly on the rise as a cause of morbidity and mortality in low- and middle-income countries (LMICs). However, despite the increasing importance of immune checkpoint inhibitors (ICIs) as a pillar of cancer therapy, access in these settings lags well behind that in high-income countries (HICs). Increasing the evaluation of ICIs through local clinical trials and demonstration projects, and inclusion in multinational clinical trials is the first step to improving access. In particular, the epidemiology and clinical presentation of cancer in LMICs is often distinct from that in HICs, and the impact of immune checkpoint blockade in these settings is understudied. Moreover, unique patterns of comorbidities, environmental factors, genetic diversity, and paucity of supportive infrastructure may all impact the risk-benefit and outcomes of cancer immunotherapy treatment. Local clinical trials not only directly impact the strengthening of infrastructure but also provide local authorities with better insight into the health economic benefit of cancer immunotherapy, giving impetus to adoption and reimbursement efforts. More local, regional, and multinational collaborative efforts are needed to speed up the evaluation, access, and adoption of ICIs throughout the developing world.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.